Female subjects | Male subjects | |
---|---|---|
Total, N | 4665 | 4287 |
Age (years) | 57.0 ± 12.2 | 57.9 ± 12.6* |
Diabetes, N (%) | 521 (11.2) | 722 (16.8)* |
Smoker, N (%) | 910 (19.5) | 965 (22.5)* |
Hypertension, N (%) | 2094 (44.9) | 2350 (54.8)* |
Statin therapy, N (%) | 423 (9.1) | 707 (16.5)* |
CKD risk groups, N (%) | ||
Low CKD risk | 3911 (83.8) | 3526 (82.2)* |
Moderate CKD risk | 518 (11.1) | 506 (11.8) |
High CKD risk | 117 (2.5) | 144 (3.4)* |
Very high CKD risk | 42 (0.9) | 53 (1.2) |
BMI (kg/m2) | 27.1 ± 5.4 | 27.6 ± 4.2* |
WHR | 0.9 ± 0.1 | 1.0 ± 0.1* |
SBP (mmHg) | 125.1 ± 17.2 | 131.7 ± 15.5* |
DBP (mmHg) | 73.9 ± 9.6 | 76.7 ± 9.9* |
Cystatin C (mg/l) | 0.9 ± 0.2 | 1.0 ± 0.2* |
eGFRCys (ml/min per 1.73m2) | 86.0 ± 19.1 | 86.8 ± 20.2 |
Urinary albumin-creatinine ratio (mg/g) | 18.6 ± 118.6 | 29.6 ± 214.4* |
Fasting glucose (mmol/l) | 5.5 ± 1.1 | 5.9 ± 1.2* |
Fasting insulin (pmol/l) | 62.6 ± 113.7 | 70.6 ± 54.6* |
HbA1c (%) | 5.4 ± 0.5 | 5.4 ± 0.6* |
Total cholesterol (mmol/l) | 5.7 ± 1.1 | 5.4 ± 1.1* |
HDL cholesterol (mmol/l) | 1.8 ± 0.5 | 1.4 ± 0.4* |
Non-HDL cholesterol (mmol/l) | 3.9 ± 1.1 | 4.0 ± 1.1* |
LDL cholesterol (mmol/l) | 3.5 ± 1.0 | 3.5 ± 1.0 |
TG (mmol/l) | 1.2 ± 0.7 | 1.6 ± 1.3* |
ApoA1 (g/l) | 1.8 ± 0.3 | 1.5 ± 0.2* |
ApoB (g/l) | 1.1 ± 0.3 | 1.1 ± 0.3* |
Lp(a) (g/l) | 0.2 ± 0.3 | 0.2 ± 0.3* |
hsCRP (mg/l) | 3.1 ± 6.1 | 2.5 ± 4.7* |
IL-6 (ng/l) | 3.5 ± 4.7 | 3.8 ± 4.9* |
ALAT (μkat/l) | 0.4 ± 0.2 | 0.5 ± 0.3* |
ASAT (μkat/l) | 0.4 ± 0.1 | 0.5 ± 0.2* |
AP (μkat/l) | 1.2 ± 0.4 | 1.1 ± 0.3 |
GGT (μkat/l) | 0.5 ± 0.6 | 0.8 ± 0.9* |